BiotechTube

Low dose DFD07 once daily + High dose DFD07 once daily + High dose DFD07 twice daily + Placebo twice daily

Phase 2/3Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Actinic Keratosis (AK)

Conditions

Actinic Keratosis (AK)

Trial Timeline

Feb 14, 2017 → Jul 5, 2018

NCT ID
NCT03116698

About Low dose DFD07 once daily + High dose DFD07 once daily + High dose DFD07 twice daily + Placebo twice daily

Low dose DFD07 once daily + High dose DFD07 once daily + High dose DFD07 twice daily + Placebo twice daily is a phase 2/3 stage product being developed by Dr. Reddy's Laboratories for Actinic Keratosis (AK). The current trial status is completed. This product is registered under clinical trial identifier NCT03116698. Target conditions include Actinic Keratosis (AK).

What happened to similar drugs?

7 of 20 similar drugs in Actinic Keratosis (AK) were approved

Approved (7) Terminated (1) Active (13)
✅fluorouracil cream 0.5%SanofiApproved
✅Imiquimod + DiclofenacViatrisApproved
✅Imiquimod + DiclofenacViatrisApproved
✅Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelAlmirallApproved
✅Tirbanibulin 2.5 mg ointmentAlmirallApproved
✅TirbanibulinAlmirallApproved
✅Ameluz 10% Topical GelBiofronteraApproved

Hype Score Breakdown

Clinical
15
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03116698Phase 2/3Completed

Competing Products

20 competing products in Actinic Keratosis (AK)

See all competitors
ProductCompanyStageHype Score
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
44
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
44
Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical GelSun PharmaceuticalPhase 1
29
Imiquimod Topical Cream 3.75% + Zyclara® (imiquimod) Topical Cream 3.75% + Vehicle Topical CreamSun PharmaceuticalPhase 1
29
Imiquimod 5% manufactured by Taro + Aldara - Imiquimod 5% + Imiquimod Vehicle manufactured by TaroSun PharmaceuticalPhase 1
29
Investigational Treatment + Active comparatorNovartisPhase 2
35
KX01 ointment 1% + PlaceboPharmaEssentiaPhase 3
40
FluorouracilSanofiPhase 1/2
32
fluorouracil cream 0.5%SanofiApproved
43
Imiquimod + DiclofenacViatrisApproved
40
Imiquimod 5 % CreamViatrisPhase 2
32
ImiquimodViatrisPre-clinical
23
Aldara (Imiquimod)ViatrisPhase 3
37
Imiquimod + DiclofenacViatrisApproved
40
Placebo Gel + LAS41005 + LAS106521AlmirallPhase 3
34
5-fluorouracil/salicylic acid + VehicleAlmirallPhase 3
34
50 mg of KX2-391 Ointment 1% + 50 mg of KX2-391 Ointment 1%AlmirallPhase 2
29
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelAlmirallApproved
41
KX2-391 Ointment 1% + PlaceboAlmirallPhase 3
34
Tirbanibulin 2.5 mg ointmentAlmirallApproved
37